Highlight
This international registry study demonstrates that treatment with KIT D816V-selective tyrosine kinase inhibitors (TKIs) in patients with systemic mastocytosis associated with a myeloid neoplasm (SM-AHN) is associated with significantly longer overall survival and substantially lower incidence of acute myeloid leukemia (AML) transformation at 36 months.
Study Background
Specialty calculators
For clinical reference; use professional judgment.
